90561-75-4

Usage

General Description

2-(4-bromophenyl)cyclopropanamine, also known as bromadol, is a psychoactive chemical substance that belongs to the class of cyclopropane compounds. It is a powerful synthetic opioid analgesic that acts as a μ-opioid receptor agonist and has been found to possess potent analgesic properties. This chemical has gained attention within the scientific and recreational drug communities for its high potency and potential for abuse. Due to its opioid-like effects, 2-(4-bromophenyl)cyclopropanamine can be highly addictive and has been associated with serious health risks, including respiratory depression and overdose. As a result, it is considered a controlled substance in many countries and is regulated for medical and research use only.

Upstream product

• 53582-00-6 ethyl trans-2-(p-bromophenyl)-1-cyclopropanecarboxylate 
• 1418287-95-2 (±)-trans-O-tert-butyl-N-(2-(4-bromophenyl)cyclopropyl)carbamate 
• 6142-65-0 trans-(1S,2S)/(1R,2R)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 65591-79-9 (E)-1-(4-Bromo-phenyl)-pent-1-en-3-one 

Relevant academic research and scientific papers

Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1

Post-translational modifications of histone play important roles in gene transcription. Aberrant methylation of histone lysine sidechains have been often found in cancer. Lysine specific demethylase 1 (LSD1), which can demethylate histone H3 lysine 4 (H3K4) and other proteins, has recently been found to be a drug target for acute myeloid leukemia. To understand structure activity/selectivity relationships of LSD1 inhibitors, several series of cyclopropylamine and related compounds were synthesized and tested for their activities against LSD1 and related monoamine oxidase (MAO) A and B. Several cyclopropylamine containing compounds were found to be highly potent and selective inhibitors of LSD1. A novel series cyclopropylimine compounds also exhibited strong inhibitory activity against LSD1.Structure activity relationships (SAR) of these compounds are discussed. Docking studies were performed to provide possible binding models of a representative compound in LSD1 and MAO-A. Moreover, these modeling studies can rationalize the observed SARs and selectivity.